<DOC>
	<DOC>NCT00845832</DOC>
	<brief_summary>This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate. In Part 1 of the study, patients will be randomized to receive either MabThera 0.5g iv or placebo on days 1 and 15, follo wed by RoActemra at one of the ascending doses between 2mg/kg and 8mg/kg at week s 4, 8 and 12 (MabThera arm) or 8mg/kg (placebo arm). In Part 2, additional pati ents will be randomized to one of 2 groups to receive MabThera 0.5g on days 1 an d 15 followed by the selected dose (from Part 1)of RoActemra at weeks 4, 8 and 1 2, or placebo on days 1 and 15 followed by RoActemra 8mg/kg at weeks 4,8 and 12. All patients will then be eligible to receive extension treatment withRoActemra every 4 weeks. The anticipated time on study treatment is 12 months, and the tar get sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patients, 1865 years of age; rheumatoid arthritis, functional status IIII; SJC&gt;=4 (28 joint count) and TJC&gt;=4 (28 joint count) at screening and baseline; RF and/or antiCCP positive; may have failed up to 1 approved antiTNF agent (infliximab, etanercept or adalimumab); inadequate response to methotrexate, at a dose of 7.525mg weekly for at least 12 weeks, at a stable dose for past 4 weeks. rheumatic autoimmune disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis; history of, or current, inflammatory joint disease other than rheumatoid arthritis; diagnosis of juvenile idiopathic arthritis and/or rheumatoid arthritis before age 16; significant cardiac or pulmonary disease; previous treatment with any biologic agent for rheumatoid arthritis (other than infliximab, etanercept or adalimumab).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>